Results 161 to 170 of about 79,007 (279)

Innovative Drug Delivery Systems for the Treatment of Glaucoma

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 2, June 2026.
This review aims to provide a comprehensive overview of current topical drug delivery strategies for ocular hypotensive agents in glaucoma therapy. Additionally, it discusses the potential impact of emerging nanotechnological and biomaterial‐based systems in shaping the future of ophthalmic drug delivery, with an emphasis on enhancing efficacy, safety,
Jing Chu   +9 more
wiley   +1 more source

Exploring and Targeting the Connection of Iron and Copper Homeostasis to Neurodegenerative Diseases

open access: yesMedComm, Volume 7, Issue 6, June 2026.
Iron and copper dyshomeostasis, along with their interactions with key intrinsically disordered proteins (e.g., Aβ, tau, α‐synuclein) have a strong implication in the onset and progression of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Prion diseases (PrDs), Huntington's disease (HD), Wilson's disease (WD),
Xin Liu   +9 more
wiley   +1 more source

Anterior chamber flare and central macular thickness after trabeculectomy versus after phacoemulsification

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page 402-409, June 2026.
Abstract Purpose To compare the inflammatory response in the eye after trabeculectomy to after phacoemulsification, focusing on anterior chamber flare (AC flare) and central macular thickness (CMT). Methods Data from 436 participants in two randomized controlled trials were analysed.
Yasmeen Ahmed   +5 more
wiley   +1 more source

The prechoroidal cleft in neovascular age‐related macular degeneration

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page 364-375, June 2026.
Abstract The prechoroidal cleft is a lenticular, hypo‐reflective space on optical coherence tomography imaging, located between a band of fibrovascular material underneath the retinal pigment epithelium (RPE) and Bruch's membrane. It occurs in 8%–22% of neovascular age‐related macular degeneration (nAMD) eyes, most often with macular neovascularization
Niels J. Brouwer   +3 more
wiley   +1 more source

Vitreoretinal complications and surgical outcomes in patients with X‐linked retinoschisis

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page 410-422, June 2026.
Abstract Purpose X‐linked retinoschisis (XLRS) is an inherited vitreoretinal disorder characterized by macular retinoschisis. In a subgroup of patients, peripheral retinoschisis can occur, potentially leading to complications such as vitreous haemorrhage (VH) and retinal detachment (RD).
Jonathan Hensman   +11 more
wiley   +1 more source

Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page e382-e396, June 2026.
Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper   +9 more
wiley   +1 more source

Normative Data for Macular Thickness and Volume for Optical Coherence Tomography in a Diabetic Population without Maculopathies. [PDF]

open access: yesJ Clin Med, 2023
Arruabarrena C   +5 more
europepmc   +1 more source

Seasonal variation in the incidence of central serous chorioretinopathy: A systematic review and meta‐analysis

open access: yesActa Ophthalmologica, Volume 104, Issue 4, Page 355-363, June 2026.
Abstract Central serous chorioretinopathy (CSC) is a chorioretinal disease characterised by serous subretinal fluid (SRF) in the macula, resulting in sudden central vision loss. It predominantly affects working‐age adults, particularly men aged 30 to 60 years.
I. Made Ferdiko Hutamadella   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy